Global Viral Vector and Vaccine Market – Industry Trends and Forecast to 2030

Análisis y tamaño del mercado de vectores virales y vacunas

La introducción de nuevas terapias basadas en vectores, como la terapia génica y la terapia celular, ha despertado un gran interés en la comunidad médica en las últimas décadas. Las terapias que implican la modificación genética, como la introducción de ADN o genes terapéuticos en el cuerpo o la célula de un paciente, han demostrado ser muy prometedoras en el tratamiento del cáncer, la enfermedad de Alzheimer, la enfermedad de Parkinson y la artritis reumatoide, entre otros trastornos.

Data Bridge Market Research analiza que el mercado de vectores virales y vacunas, que es de USD 513,43 millones en 2022, se espera que alcance los USD 2016,62 millones para 2030, a una CAGR del 18,65% durante el período de pronóstico de 2023 a 2030. Además de los conocimientos sobre escenarios de mercado como el valor de mercado, la tasa de crecimiento, la segmentación, la cobertura geográfica y los principales actores, los informes de mercado seleccionados por Data Bridge Market Research también incluyen un análisis profundo de expertos, epidemiología del paciente, análisis de la cartera, análisis de precios y marco regulatorio.

Alcance y segmentación del mercado de vectores virales y vacunas

Definición de mercado

Un vector es un tipo de dispositivo de administración de genes que se utiliza para introducir un transgén en una célula donde puede replicarse y/o expresarse. El vector es una molécula de ADN que contiene un inserto transgénico, así como una secuencia más larga que actúa como pilar del vector. Las funciones básicas del vector para transmitir información genética a otra célula son el aislamiento, la multiplicación o la expresión del inserto en la célula diana.

Dinámica del mercado de vacunas y vectores virales

Conductores

• Aumento de la prevalencia del cáncer y de los trastornos genéticos

Según la Organización Mundial de la Salud, el cáncer de pulmón es la principal causa de muerte por cáncer, seguido del cáncer de mama y el cáncer colorrectal. Uno de los principales impulsores del mercado mundial de vectores virales y vacunas es la creciente prevalencia del cáncer, las enfermedades genéticas y las enfermedades infecciosas, que está aumentando la demanda de tratamientos genéticos basados ​​en vectores, terapias celulares y vacunas.

• Rápida adopción de vectores virales y plasmídicos para el desarrollo de terapias innovadoras

Se están desarrollando nuevos medicamentos a un ritmo acelerado utilizando vectores virales y no virales. Estos vectores pueden administrar un gen a una célula o tejido específico in vivo. Los virus adenoasociados, los lentivirus y los retrovirus son ejemplos de vectores virales utilizados en ensayos clínicos y preclínicos para evaluar productos de terapia génica y celular y vacunas.

Oportunidades

• Aumento de la prevalencia de enfermedades

La creciente prevalencia de enfermedades como las cardiopatías, el cáncer, el VIH y la hemofilia ha hecho necesario el desarrollo de terapias basadas en vectores virales, y los avances tecnológicos en la fabricación de vectores virales impulsan el crecimiento del mercado. Además, el uso cada vez mayor de vectores virales en la industria biofarmacéutica, así como la necesidad de tratamientos más rentables, están impulsando la demanda del mercado. Sin embargo, la industria médica subdesarrollada en algunas áreas, así como el aumento de las actividades gubernamentales en el sector de I+D de la atención sanitaria, brindarán oportunidades rentables en los próximos años.

Restricciones/Desafíos

• Alto costo

The lack of skilled professionals and high cost are factors restraining market growth. The main disadvantages of viral vector vaccines are that they have a more complex manufacturing process, they risk genomic integration, host-induced neutralising antibodies to the carrier virus can develop, and/or it may not be possible to use the same technology for repeated vaccinations.
This viral vector and vaccine market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the viral vector and vaccine market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Viral Vector and Vaccine Market

Due to the devastating COVID-19 pandemic, vaccine development against SARS-CoV-2 has been intense, encompassing all conceivable options for providing the global community with safe and effective vaccine candidates in the shortest timeframe possible. Viral vectors, particularly adenovirus-based vectors, have been crucial. Vaccines based on viral vectors such as vaccinia, measles, rhabdoviruses, influenza viruses, and lentiviruses have also been developed. Self-amplifying RNA viral vectors delivered by lipid nanoparticles were used to create COVID-19 vaccines. Several adenovirus-based vaccine candidates elicited strong immune responses in inoculated animals, and mice and primates were shielded from challenges. Furthermore, adenovirus-based vaccination candidates have gone through phase I, II, and III clinical trials. The simian adenovirus-based ChAdOx1 vector expressing the SARS-CoV-2 S spike protein was recently approved for use in clinical trials in the UK.

Recent Development

• In 2019, The US Food and Drug Administration approved Zolgensma (onasemnogene abeparvovec-xioi), an adeno-associated virus vector-based gene therapy for the treatment of pinal muscular atrophy (SMA) in infants under the age of two.

Global Viral Vector and Vaccine Market Scope

The viral vector and vaccine market is segmented on the basis of type, workflow, application, disease and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Adenovirus
• Fowlpox Virus
• Attenuated Yellow Fever
• Vaccinia Virus Vectors
• Others

Workflow

• Upstream Processing
• Downstream Processing

Application

• Antisense and RNAi
• Gene Therapy
• Cell Therapy
• Vaccinology

 Disease

• Cancer
• Genetic Disorders
• Infectious Diseases
• Others

End-User

• Pharmaceutical and Biopharmaceutical Companies
• Research Institutes

Viral Vector and Vaccine Market Regional Analysis/Insights

The viral vector and vaccine market is analyzed and market size insights and trends are provided by country, type, workflow, application, disease and end-user as referenced above.

The countries covered in the viral vector and vaccine market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America is anticipated to dominate the market share due to increasing infectious disease patients.

Asia-Pacific is expected to be fastest growing region in forecast period due to clinical transformation and industrialization of gene therapy manufacturing.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure Growth Installed base and New Technology Penetration

The viral vector and vaccine market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for viral vector and vaccine market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the viral vector and vaccine market. The data is available for historic period 2011-2021.

Competitive Landscape and Viral Vector and Vaccine Market Share Analysis

The viral vector and vaccine market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to viral vector and vaccine market.

Some of the major players operating in the viral vector and vaccine market are:

• Novasep (France)
• MerckKGaA (Germany)
• Charles River Laboratories (U.K.)
• uniQure N.V. (Netherlands)
• Waisman Biomanufacturing  (U.S.)
• Creative-Biogene (U.S.)
• Aldevron (U.S.)
• Addgene (U.S.)
• Oxford Biomedica (U.K.)
• Thermo Fisher Scientific Inc (U.S.)
• Fujifilm Corporation (Japan)
• Spark Therapeutics Inc. (U.S.)
• ABL Inc. (U.S.)
• Boehringer Ingelheim International GmbH (Germany)
• Brammer Bio (U.S.)
• Creative Biogene
• General Electric (U.S.)
• Pfizer Inc. (U.S.)

SKU-54427